That's an issue we're continuing to work on, and this is in conjunction with other departments that are more directly involved in the pharmaceutical area. We have been doing an evaluation of the potential costs and doing some modelling of what the expectations would be for those costs. There will also have to be a discussion with the provinces and territories to get their perception of what kinds of cost increases they could expect. We'll have to come to an understanding following that.
On February 16th, 2016. See this statement in context.